Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-immune plasma
- Development stage
- Discontinued
- Lead developer
- BioAegis Therapeutics
- Administration
- Intravenous
01
Overview
Non-immune plasma refers to blood plasma collected from donors who have not developed antibodies against SARS-CoV-2. Unlike convalescent plasma therapy which uses blood from people who've recovered from COVID-19 to help others recover, non-immune plasma lacks the specific antibodies that would recognize and neutralize the SARS-CoV-2 virus. Non-immune plasma is often used as a control in studies evaluating the efficacy of convalescent plasma therapy.
- Other names
- SARS-CoV-2 non-immune plasmaSARS-CoV2 non-immune plasmaSARS-CoV 2 non-immune plasma
Beyond the preview
Go deeper on non-immune plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-immune plasma.